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Abstract
Background: The advent of standardized classification and assessment of psychiatric disorders,
and considerable joint efforts among many countries has led to the reporting of international rates
of psychiatric disorders, and inevitably, their comparison between different racial groups.
Results: In neurologic diseases with defined genetic etiologies, the same genetic cause has different
phenotypes in different racial groups.
Conclusion: We suggest that genetic differences between races mean that diagnostic criteria
refined in one racial group, may not be directly and simply applicable to other racial groups and
thus more effort needs to be expended on defining diseases in other groups. Cross-racial
confounds (in addition to cultural confounds) make the interpretation of rates in different groups
even more hazardous than seems to have been appreciated.
Text
The DSM [1] and ICD [2] psychiatric disorder criteria rep-
resent the extracted wisdom of predominantly Caucasian
psychiatrists treating predominantly Caucasian patients.
They have been useful clinically for the important prag-
matic reasons that, within this group, they facilitate effi-
cient communication between physicians about patients,
reporting on morbidity and mortality statistics, attempts
at common treatments, and billing of third party payers.
However, they have little biological validity and there is
no evidence that they reflect etiology. They have opened
the door to many pharmacologic and behavioral interven-
tion trials [3-6] and etiologic investigations that have, in
general, been disappointing. However, these disordered
symptom clusters (often comprised of variations in nor-
mal human feelings) reflect complexity that we have not
been able to fully appreciate and this is in part due to our
obscured vision of them through the lens of DSM/ICD
classification.
Despite this derivation, cross-racial comparisons of disor-
der rates are a frequent topic of investigation and interpre-
tation [7,8]. While most researchers would accept that it is
challenging to compare diagnostic rates of psychiatric dis-
orders across cultures [9] they have not considered the
possibility that clinical manifestations of the same etiol-
ogy may be different in people of different genetic back-
grounds (that is, their race).
While clinical neurological diagnoses are essentially made
by the same operational process of clinical consensus,
these clinical diagnoses have traditionally been validated
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through neuropathological examination. In many cases,
this biological validation can be made since the genetic
etiologies of many neurological diseases are now known.
In the limited number of times this biological validation
has been compared retrospectively against the clinical
(and pathologic) characterization of neurological disease,
it has become clear that the clinical characterization holds
up poorly in different racial groups. For example, the phe-
notypes of both Spinocerebellar Ataxia types 2 and 3
(SCA2 and SCA3) are different in Eastern Asians and Sub-
Saharan-Africans  respectively from their phenotypes in
Caucasians [10-13]. Dentatorubral-Pallidoluysian Atro-
phy in the Japanese is different from Haw River syndrome
in African-Americans despite being caused by the same
polyglutamine expansion [14,15]. Presenilin mutations
present with Alzheimer's disease with a predominantly
early memory change in Caucasians, but seem to present
with personality change in those of African descent [16].
These differences in clinical phenotypes are reminiscent of
the differences seen in different strains of transgenic mice
with the same transgene [17] and should not be surprising
to geneticists [18,19]. The process of validation through
biological examination is not possible in psychiatric diag-
noses (though many attempts are underway in the search
for "endophenotypes" or biomarkers); in fact, many psy-
chiatric syndromes are mimicked by known medical dis-
orders, such as, hyper/hypothyroidism, pancreatic cancer,
hyperparathyroidism, lyme disease (mood changes,
mania, depression); hypo/hyperglycemia, pheochromo-
cytoma (panic), thiamine deficiency, normal pressure
hydrocephalus (dementia, cognitive changes), lead poi-
soning (attention deficit hyperactivity disorder), etc., and
a psychiatric diagnosis is only made following their exclu-
sion, as the DSM-IV dictates.
Given this precedent, it seems ill advised to interpret any
differences in disorder rates between different racial
groups as being indicative of different rates of exposures
to risk factors. This potential for confounding genetic var-
iability is in addition to the more widely recognized, cul-
turally derived issues inherent in the interpretation of
most "risk factors" in psychiatric disorders, such as parent-
ing styles, low socioeconomic status, temperament, or
psychological "trauma." Since the diagnostic criteria have
been imperfectly tuned to ensure, as far as possible, that
everyone with mental illness in a Caucasian population
receives a diagnosis (for billing, treatment, etiologic study
and needs assessment surveys), it should not be surprising
to find that the rates in non-Caucasians would be differ-
ent. Therefore, even given identical exposures, one should
expect lower rates of DSM/ICD categories in non-Cauca-
sians since less people in those groups would fit comfort-
ably a diagnostic category. The limited data available
suggest this is generally the case [18]. This does not imply
that the burden of mental distress is less in other races, but
rather our instruments of assessment and diagnosis are
less appropriately applied in such genetically different
individuals.
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